Digital Press Kit
SenoBright: A Breakthrough in Breast Cancer Imaging
New technology produces optimized images, enables physicians to diagnose with greater certainty
With the launch of SenoBright, GE Healthcare again demonstrates its leadership in mammography research and development. SenoBright Contrast Enhanced Spectral Mammography (CESM) technology reduces ambiguity in screening results, enabling physicians to detect and diagnose cancer in dense breast tissue more rapidly and accurately.
The new technology works with an upgrade to GE Healthcare’s Senographe DS and Senographe Essential digital mammography equipment. To generate an enhanced image, SenoBright uses X-rays at multiple energies to create two separate exposures, specifically illuminating and highlighting areas where there is angiogenesis.
In this press kit you will find background documents, images and video explaining the new technology, its implications for early breast cancer detection and diagnosis and the benefits to patients.
Note: The SenoBright option cannot be put into service until it has been made to comply with CE marking. It may not be available in all regions, and it is not cleared or approved for sale in the U.S. by the FDA.
Press Contact:
Allison Cohen
+972 547 299 742
allison.cohen@med.ge.com
Press Kit Downloads
Press Documents
- Fact Sheet: Contrast Enhanced Spectral Mammography
- Fact Sheet: GE Healthcare Mammography
- Fact Sheet: Sensitivity and Specificity with SenoBright
Videos & Podcasts
Images
Quotes
"A CESM exam takes from 5 to 10 minutes. During my investigation of the use of CESM with my own examinations of patients, I have been able to better define the spread of a cancer compared to standard mammography and ultrasound, and follow-up exams with an MRI validated exactly the same results. Moreover, in the majority of cases the confidence in the diagnosis is high enough that the patient can be told the results that same day.
Dr. Clarisse Dromain, Gustave Roussy Cancer Institute, France.
“GE Healthcare is pleased to bring to market such advanced breast imaging technologies like SenoBright, the result of over 10 years and $12 million investment of research and clinical collaborations. This innovative technology will support the earlier diagnosis of this prevalent disease, by providing access to new diagnostic information at a lower cost.”
Reinaldo Garcia, President and CEO of GE Healthcare for Europe, Middle East and Africa (EMEA)
“Given our proven history of breast imaging innovations, GE is proud to release yet another innovative technology, soon to be available to much of our digital installed base. We are one of the only companies today to engineer and manufacture the entire mammography imaging chain from tube, and detector to review workstation, coupled with integration of the comprehensive local requirements for each customer. SenoBright is likely to be a key enabler of accelerated patient workflow from diagnostics to treatment planning. It is enhancing the widely accepted technology of digital mammography by adding the functional information in order to detect angiogenesis.”
David Caumartin, General Manager Mammography, GE Healthcare
